REMOGEN® Omega Versus Cationorm® in the Treatment of Patients Suffering From Dry Eye

A Multicentre Randomized Trial Comparing the Efficacy and Safety of REMOGEN® Omega Versus Cationorm® in the Treatment of Patients Suffering From Dry Eye

The efficacy and safety of Remogen® Omega in the treatment of dry eye signs and symptoms will be investigated in comparison to Cationorm®.

Inclusion Criteria:

• With at least a 3-month documented history of bilateral dry eye
• With a score of ocular surface staining with fluorescein (OSSF) ≥ 4 and ≤ 9 on the Oxford scale
• With at least one objective sign of tear deficiency
• With Ocular Surface Disease Index (OSDI) score of ≥ 18

Exclusion Criteria:

• Refractive surgery within 12 months prior to selection
• Any other ocular surgery or ocular trauma within 6 months prior to selection
• Systemic or local use of one of the following medications: glucocorticosteroids, cyclosporine A, antibiotics, NSAIDs